LipoScience, Inc. (Nasdaq:LPDX) announced the termination of its relationship with Health Diagnostics Laboratory, Inc. (“HDL Inc.”), one of its laboratory customers. On March 17, 2014, HDL Inc. began offering its own non-FDA cleared test for the measurement of low density lipoprotein particles (“LDL-P”). While the NMR LipoProfile® test may continue to be made available to HDL Inc. customers, LipoScience would like to ensure that physicians are able to differentiate with certainty which test result they are receiving. In order to ensure that patients and physicians are aware of and have unlimited access to the NMR LipoProfile® test, the only FDA-cleared and clinically validated test for measuring LDL-P and for managing patients with cardiovascular disease, LipoScience has terminated its contractual relationship with HDL Inc. The Company plans to mitigate the effects of loss of revenues from HDL Inc. by focusing on its relationships with other national, regional and local lab partners and by alerting physicians to use LipoScience lab partners that offer the NMR LipoProfile test. LipoScience Inc(NASDAQ:LPDX) shares after opening at $3.63 moved to $3.63 on last trade day and at the end of the day closed at $3.03. Company price to sales ratio in past twelve months was calculated as 0.84 and price to cash ratio as 0.86. LipoScience Inc (NASDAQ:LPDX) showed a negative weekly performance of -25.00%.
Clovis Oncology (Nasdaq:CLVS) 13.2% LOWER; pulling back following a 3.6 percent gain Thursday. The company updated findings from the Phase 1 portion of its ongoing Phase 1/2 clinical study of CO-1686, the Company’s novel, oral, targeted covalent (irreversible) inhibitor of mutant forms of the epidermal growth factor receptor (EGFR) for the treatment of non-small cell lung cancer in patients with initial activating EGFR mutations as well as the dominant resistance mutation T790M. Interim results from the Phase 1 dose-escalation portion of this Phase 1/2 study are being presented in an oral presentation by Dr. Heather Wakelee at the 4th European Lung Cancer Conference (ELCC) in Geneva. Clovis Oncology Inc (NASDAQ:CLVS) shares fell -12.44% in last trading session and ended the day on $70.33. CLVS return on equity ratio is recorded as -25.50% and its return on assets is -22.30%. Clovis Oncology Inc (NASDAQ:CLVS) yearly performance is 145.31%.
Therapeutics MD (NASDAQ:TXMD) CEO Robert G. Finizio unloaded 982,053 shares of the company’s stock in a transaction that occurred on Wednesday, March 26th. The stock was sold at an average price of $6.70, for a total transaction of$6,579,755.10. Therapeutics MD Inc (NYSEMKT:TXMD) shares moved down -0.83 % in last trading session and was closed at $6.00, while trading in range of $5.21 – 6.12 . Therapeutics MD Inc (NYSEMKT:TXMD) year to date (YTD) performance is 15.16%.
Stock analysts at JMP Securities increased their price objective on shares of Durata Therapeutics (NASDAQ:DRTX) from $14.00 to $18.00 in a report issued on Tuesday, StockRatingsNetwork reports. The firm currently has an “outperform” rating on the stock. JMP Securities’ price target points to a potential upside of 26.67% from the company’s current price. Durata Therapeutics Inc (NASDAQ:DRTX) weekly performance is -9.40%. On last trading day company shares ended up $13.50. Durata Therapeutics Inc (NASDAQ:DRTX) distance from 50-day simple moving average (SMA50) is 2.00%. Analysts mean target price for the company is $17.18.